Resection Should be Considered for Residual Non-Retroperitoneal Disease in Post-Chemo NSGCTs
Although patients with metastatic nonseminomatous germ-cell tumors who had teratoma in the primary tumor were found to have a higher rate of teratoma in residual non-retroperitoneal disease following chemotherapy, those without teratoma in the primary tumor could have teratoma or active testicular germ-cell tumors in residual disease post-chemotherapy and should be considered for resection.
Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer
June 1st 2023Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.
REGN5459 Demonstrates Early Promise in Heavily Pretreated Multiple Myeloma
May 9th 2023Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.
REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma
April 17th 2023The BCMA- and CD3-directed bispecific antibody REGN5459 led to fast onset, deep, and dose-dependent responses sustained over time, with a high frequency of manageable low-grade cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural Indiana
April 10th 2023Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Camidge and Jalal on Setting up an Infrastructure for Success in Life and Work
March 23rd 2023In this episode of ‘How This is Building Me,’ Camidge sits down with Jalal to discuss her transition from life in Jordan to Indianapolis, Indiana, the realities of being a mother in medicine, the importance of transparency in academia, and more.
Dr. O'Neil on Neuroendocrine Tumors
May 22nd 2018Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).
Indiana University Researchers Find Precision Medicine Improves Outcomes
October 14th 2016With the growing body of evidence supporting positive outcomes with the use of precision medicine–based approaches, academic cancer centers are increasingly incorporating genomic technology into standard clinical care.
Summer Research Program Offers First-Hand Experiences
June 14th 2016The program brings both high-school and undergraduate students from underrepresented populations to the IU School of Medicine's Indianapolis campus. It offers students positive and meaningful firsthand exposure to biomedical and behavioral science careers that might not otherwise present themselves.
Combination Therapies Explored in Pancreatic Cancer Subgroups
March 25th 2016To address the unmet need for better diagnostic and therapeutic modalities in pancreatic cancer, investigators at the Indiana University School of Medicine have established the Pancreatic Cancer Signature Center at the Indiana University Melvin and Bren Simon Cancer Center.